Amgen Inc. $AMGN Shares Acquired by Hodges Capital Management Inc.

Hodges Capital Management Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 75.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,424 shares of the medical research company’s stock after purchasing an additional 3,620 shares during the period. Hodges Capital Management Inc.’s holdings in Amgen were worth $2,964,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. High Note Wealth LLC raised its position in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares in the last quarter. TAGStone Capital Inc. grew its position in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after buying an additional 28 shares in the last quarter. Verus Capital Partners LLC increased its stake in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after buying an additional 28 shares during the period. Destination Wealth Management increased its stake in shares of Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after buying an additional 29 shares during the period. Finally, Breakwater Capital Group raised its holdings in Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 29 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AMGN shares. Mizuho boosted their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday, June 16th. UBS Group lifted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Wells Fargo & Company boosted their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Morgan Stanley increased their target price on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, June 9th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $356.00.

Amgen Stock Down 2.1%

AMGN stock opened at $366.44 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company’s 50 day moving average is $342.43 and its two-hundred day moving average is $348.09. The stock has a market cap of $197.77 billion, a P/E ratio of 25.50, a PEG ratio of 3.68 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts expect that Amgen Inc. will post 22.39 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Zacks upgraded Amgen to a Buy (Rank #2), signaling improving earnings outlook and potentially supporting the stock in the near term. Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
• Positive Sentiment: Truist raised its price target on Amgen from $327 to $340, indicating somewhat better valuation expectations, even while keeping a Hold rating. Benzinga report on Truist price target increase
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating with a $350 target, suggesting the stock is viewed as fairly valued relative to recent levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Amgen’s stock also drew attention from market commentary noting it had been slipping while the broader market advanced, reflecting relative underperformance rather than a company-specific catalyst. Amgen (AMGN) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Investor sentiment remains weighed down by Tavneos scrutiny, including FDA efforts to challenge the drug’s approval and the retraction of a key supporting study, which could cloud Amgen’s sales outlook and pipeline confidence. Amgen Slides as Tavneos Scrutiny and Pipeline Questions Weigh on Shares

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.